Compare DSP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSP | NMRA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.6M | 302.0M |
| IPO Year | 2021 | 2023 |
| Metric | DSP | NMRA |
|---|---|---|
| Price | $12.58 | $1.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $17.81 | $7.50 |
| AVG Volume (30 Days) | 203.7K | ★ 687.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $0.83 |
| 52 Week High | $14.80 | $3.65 |
| Indicator | DSP | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 28.21 |
| Support Level | $10.36 | $0.83 |
| Resistance Level | $13.36 | $1.74 |
| Average True Range (ATR) | 0.60 | 0.09 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 37.89 | 0.96 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.